世界の呼吸器用薬市場見通し2027

◆英語タイトル:Global Respiratory Drugs Market Outlook 2027
◆商品コード:NEST20JN034
◆発行会社(リサーチ会社):Research Nester
◆発行日:2020年5月
◆ページ数:185
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD4,150 ⇒換算¥431,600見積依頼/購入/質問フォーム
Site License(同一拠点閲覧用)USD5,150 ⇒換算¥535,600見積依頼/購入/質問フォーム
Enterprisewide License(同一法人閲覧用)USD7,150 ⇒換算¥743,600見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はResearch Nester社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Research Nester社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Respiratory Drugs Market Analysis – 2019-2027
Respiratory disorders mainly consist of ailments affecting the lungs such as asthma, chronic obstructive pulmonary disease (COPD), acute respiratory infections, chronic bronchitis and several others.. These respiratory illnesses can be caused by a number of factors, some of them consisting of genetics, environment, and occupation as well as ageing. The market for respiratory drugs is anticipated to grow at a CAGR of 6.0% over the forecast period, i.e., 2019-2027. Further, the market is predicted to attain a significant market value of about USD 25,500 million by the end of 2027. Innovations in the healthcare industry are resulting in increasing research and development in the area of respiratory drugs. On the back of these factors, the market for respiratory drugs is anticipated to observe a significantly high growth in the next few years.
The market for respiratory drugs is segmented by drug, by formulation, by disease, by administration, by drug delivery, by distribution channel and by region. On the basis of disease, the market is segmented into asthma, chronic obstructive pulmonary disease, cystic fibrosis, pulmonary hypertension, allergic rhinitis, idiopathic pulmonary fibrosis and others. The segment for asthma is predicted to attain the largest market value of about USD 8,500 million by the end of 2027 and grow at the highest CAGR over the forecast period. A report by the Centers for Disease Control and Prevention (CDC) stated that 1 among every 13 people is estimated to suffer from asthma and adult women are more prone to this condition as compared to adult men. This can explain the growth of this segment in the coming years.
On the basis of region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. The largest market share was held by the market in North America, with a share of 40% in 2019. The market in this region is further estimated to continue holding the largest share over the forecast period. Moreover, this is closely followed by the market in Asia Pacific on the back of the rising developments and increasing innovations in the healthcare industry in the Asia Pacific region which account for the development of a higher number of respiratory drugs as compared with other regions.
Some of the key industry leaders in the global respiratory drugs market are AstraZeneca, Fibrogen Inc., Novartis International AG, Abbott Laboratories, GlaxoSmithKline plc, F. Hoffmann-la Roche AG, Merck & Co. Inc. and Sunovion Pharmaceuticals Inc.

【レポートの目次】

Global Respiratory Drugs Market
1. Report Overview
1.1. Global Respiratory Drugs Market Overview
1.2. Why You Should Read This Report
1.3. How This Report Delivers
1.4. Key Questions Answered by This Analytical Report
1.5. Who is This Report For?
1.6. Methodology
1.6.1. Primary Research
1.6.2. Secondary Research
1.6.3. Market Evaluation & Forecasting Methodology
2. Introduction to the Respiratory Drugs Market
2.1. Respiratory Drugs Market Structure
2.2. Respiratory Drugs Market Definition
2.3. Global Respiratory Drugs Market Taxonomy
2.4. Global Respiratory Drugs Market Snapshot
2.5. Epidemiology Analysis
ASTHMA
CHRONIC OBSTRUCTIVE PULMONARY DISEASE
CYSTIC FIBROSIS
PULMONARY HYPERTENSION
ALLERGIC RHINITIS
IDIOPATHIC PULMONARY FIBROSIS
2.6. Global Respiratory Drugs Market Dynamics
2.6.1. Global Respiratory Drugs Market: Driver
2.6.2. Global Respiratory Drugs Market: Restraints
2.6.1. Global Respiratory Drugs Market: Trends
2.6.1. Global Respiratory Drugs Market: Opportunities
3. Global Respiratory Drugs Market, By Drug Type, 2019-2027
3.1. Introduction
3.2. Global Respiratory Drugs Market Size and Forecast, By Drug Type
3.2.1. Anti-Asthmatics & COPD Drug Segment
3.2.2. Cough & Cold Preparations Drug Segment
3.2.3. Pulmonary Hypertension Segment
3.2.4. Idiopathic Pulmonary Fibrosis Segment
4. Global Respiratory Drugs Market, By Formulation, 2019-2027
4.1. Introduction
4.2. Global Respiratory Drugs Market Size and Forecast, By Formulation
4.2.1. Dry Powder Segment
4.2.2. Tablets & Capsules Segment
4.2.3. Sprays Segment
4.2.4. Syrups & Solutions Segment
5. Global Respiratory Drugs Market, By Disease, 2019-2027
5.1. Introduction
5.2. Global Respiratory Drugs Market Size and Forecast, By Disease
5.2.1. Asthma Segment
5.2.2. Chronic Obstructive Pulmonary Disease Segment
5.2.3. Cystic Fibrosis Segment
5.2.4. Pulmonary Hypertension Segment
5.2.5. Allergic Rhinitis Segment
5.2.6. Idiopathic Pulmonary Fibrosis Segment
5.2.7. Others Segment
6. Global Respiratory Drugs Market, By Administration, 2019-2027
6.1. Introduction
6.2. Global Respiratory Drugs Market Size and Forecast, By Administration
6.2.1. Stand Alone Drugs Segment
6.2.2. Combination Drugs Segment
7. Global Respiratory Drugs Market, By Drug Delivery, 2019-2027
7.1. Introduction
7.2. Global Respiratory Drugs Market Size and Forecast, By Drug Delivery
7.2.1. Inhalational Segment
7.2.2. Oral Segment
7.2.3. Injection Segment
8. Global Respiratory Drugs Market, By Distribution Channel, 2019-2027
8.1. Introduction
8.2. Global Respiratory Drugs Market Size and Forecast, By Distribution Channel
8.2.1. Online Segment
8.2.2. Offline Segment
9. Global Respiratory Drugs Market, By Region, 2019-2027
9.1. Introduction
9.2. Global Respiratory Drugs Market Size and Forecast, By Region
9.2.1. North America
9.2.2. Latin America
9.2.3. Europe
9.2.4. Asia Pacific
9.2.5. Middle East and Africa
10. North America Respiratory Drugs Market Analysis and Forecast, 2019-2027
10.1. Introduction
10.1.1. North America
10.2. North America Respiratory Drugs Market Forecast, By Country, 2019-2027
10.3. North America Respiratory Drugs Market Forecast, By Drug Type, 2019-2027
10.4. North America Respiratory Drugs Market Forecast, By Formulation, 2019-2027
10.5. North America Respiratory Drugs Market Forecast, By Disease, 2019-2027
10.6. North America Respiratory Drugs Market Forecast, By Administration, 2019-2027
10.7. North America Respiratory Drugs Market Forecast, By Drug Delivery, 2019-2027
10.8. North America Respiratory Drugs Market Forecast, By Distribution Channel, 2019-2027
11. Latin America Respiratory Drugs Market Analysis and Forecast, 2019-2027
11.1. Introduction
11.1.1. Latin America
11.2. Latin America Respiratory Drugs Market Forecast, By Country, 2019-2027
11.3. Latin America Respiratory Drugs Market Forecast, By Drug Type, 2019-2027
11.4. Latin America Respiratory Drugs Market Forecast, By Formulation, 2019-2027
11.5. Latin America Respiratory Drugs Market Forecast, By Disease, 2019-2027
11.6. Latin America Respiratory Drugs Market Forecast, By Administration, 2019-2027
11.7. Latin America Respiratory Drugs Market Forecast, By Drug Delivery, 2019-2027
11.8. Latin America Respiratory Drugs Market Forecast, By Distribution Channel, 2019-2027
12. Europe Respiratory Drugs Market Analysis and Forecast, 2019-2027
12.1. Introduction
12.1.1. Europe
12.2. Europe Respiratory Drugs Market Forecast, By Country, 2019-2027
12.3. Europe Respiratory Drugs Market Forecast, By Drug Type, 2019-2027
12.4. Europe Respiratory Drugs Market Forecast, By Formulation, 2019-2027
12.5. Europe Respiratory Drugs Market Forecast, By Disease, 2019-2027
12.6. Europe Respiratory Drugs Market Forecast, By Administration, 2019-2027
12.7. Europe Respiratory Drugs Market Forecast, By Drug Delivery, 2019-2027
12.8. Europe Respiratory Drugs Market Forecast, By Distribution Channel, 2019-2027
13. Asia Pacific Respiratory Drugs Market Analysis and Forecast, 2019-2027
13.1. Introduction
13.1.1. Asia Pacific
13.2. Asia Pacific Respiratory Drugs Market Forecast, By Country, 2019-2027
13.3. Asia Pacific Respiratory Drugs Market Forecast, By Drug Type, 2019-2027
13.4. Asia Pacific Respiratory Drugs Market Forecast, By Formulation, 2019-2027
13.5. Asia Pacific Respiratory Drugs Market Forecast, By Disease, 2019-2027
13.6. Asia Pacific Respiratory Drugs Market Forecast, By Administration, 2019-2027
13.7. Asia Pacific Respiratory Drugs Market Forecast, By Drug Delivery, 2019-2027
13.8. Asia Pacific Respiratory Drugs Market Forecast, By Distribution Channel, 2019-2027
14. Middle East & Africa Respiratory Drugs Market Analysis and Forecast, 2019-2027
14.1. Introduction
14.1.1. MEA
14.2. MEA Respiratory Drugs Market Forecast, By Country, 2019-2027
14.3. MEA Respiratory Drugs Market Forecast, By Drug Type, 2019-2027
14.4. MEA Respiratory Drugs Market Forecast, By Formulation, 2019-2027
14.5. MEA Respiratory Drugs Market Forecast, By Disease, 2019-2027
14.6. MEA Respiratory Drugs Market Forecast, By Administration, 2019-2027
14.7. MEA Respiratory Drugs Market Forecast, By Drug Delivery, 2019-2027
14.8. MEA Respiratory Drugs Market Forecast, By Distribution Channel, 2019-2027
15. Company Profile
15.1. ASTRAZENECA PLC
15.1.1. Overview
15.1.2. Product Type/Service Offerings
15.1.3. Key Developments
15.1.4. SWOT ANALYSIS
15.2. FIBROGEN, INC
15.2.1. Overview
15.2.2. Product Type/Service Offerings
15.2.3. SWOT Analysis
15.3. NOVARTIS INTERNATIONAL AG
15.3.1. Overview
15.3.2. Product Type/Service Offerings
15.3.3. Key Developments
15.3.4. SWOT ANALYSIS
15.4. ABBOTT LABORATORIES
15.4.1. Overview
15.4.2. Product Type/Service Offerings
15.4.3. SWOT Analysis
15.5. GLAXOSMITHKLINE PLC
15.5.1. Overview
15.5.2. Product Type/Service Offerings
15.5.3. SWOT Analysis
15.6. F. HOFFMANN-LA ROCHE AG
15.6.1. Overview
15.6.2. Product Type/Service Offerings
15.6.3. Key Developments
15.6.4. SWOT Analysis
15.7. MERCK & CO., INC
15.7.1. Overview
15.7.2. Product Type/Service Offerings
15.7.3. Strategy (s)
15.7.4. Key Developments
15.7.5. SWOT Analysis
15.8. SUNOVION PHARMACEUTICALS INC
15.8.1. Overview
15.8.2. Product Type/Service Offerings
15.8.3. SWOT Analysis
16. Respiratory Drugs Pipeline Analysis
16.1. ANTI-ASTHMATICS AND COPD DRUG
16.1.1. LONG-ACTING BETA-AGONISTS (LABA)
Study Description
Study Design
16.1.2. LONG-ACTING MUSCARINIC ANTAGONISTS (LAMA)
Study Description
Study Design
Study Description
Study Design
16.1.3. CORTICOSTEROIDS
Study Description
Study Design
Study Description
Study Design
Study Description
Study Design
16.1.4. LEUKOTRIENE
Study Description
Study Design
Study Description
Study Design
16.1.5. XANTHINES
Study Description
Study Design
16.2. COUGH AND COLD PREPARATIONS DRUG
16.2.1. ANTITUSSIVES
Study Description
Study Design
Study Description
Study Design
16.3. ANTIHISTAMINES
Study Description
Study Design
Study Description
Study Design
16.4. DECONGESTANTS
Study Description
Study Design
Study Description
Study Design
16.5. EXPECTORANTS
Study Description
Study Design
Study Description
Study Design
16.6. PULMONARY HYPERTENSION
16.6.1. ENDOTHELIN RECEPTOR ANTAGONISTS
Study Description
Study Design
16.6.2. ANTICOAGULANTS
Study Description
Study Design
Study Description
Study Design
16.7. DIURETICS
Study Description
Study Design
Study Description
Study Design
16.7.1. SOLUBLE GUANYLATE CYCLASE (SGC) STIMULATOR
Study Description
Study Design
Study Description
Study Design
16.8. IDIOPATHIC PULMONARY FIBROSIS
16.8.1. PIRFENIDONE
Study Description
Study Design
Study Description
Study Design
16.8.2. NINTEDANIB
Study Description
Study Design
Study Description
Study Design
17. Acronyms



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[世界の呼吸器用薬市場見通し2027]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆